Kinea Bio Inc. is a biotechnology company specializing in the development of innovative genetic medicines using a novel dual AAV vector platform, SIMPLI-GT™, to deliver large therapeutic genes that exceed the natural packaging capacity of AAVs. The company focuses on systemic disorders such as Duchenne muscular dystrophy and dysferlinopathy, aiming to translate breakthrough biology into transformative treatments for patients with high unmet medical needs through strategic collaborations and cutting-edge science.